ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i2.22465Keywords:
Sofosbuvir, Velpatasvir, Isocratic, High performance liquid chromatography, C18, Formic acid, MethanolAbstract
 Objectives: The purpose of the research is to develop a simple, precise, economical, accurate, reproducible, and sensitive method for the estimation of sofosbuvir and velpatasvir drug product by rp-hplc method
Methods: New Analytical method was developed for the estimation of Velpatasvir and Sofosbuvir in drug product by liquid chromatography. The chromatographic separation was achieved on C18 column (Luna 18 150*4.6mm3.0um) at ambient temperature. The separation achieved employing a mobile phase consists of 0.1%v/v Formic acid in water: Methanol: Acetonitrile (35:40:25). The flow rate was 0.8ml/ minute and ultra violet detector at 269nm. The average retention time for Velpatasvir and Sofosbuvir found to be 2.62 min and 3.72 min.
Results: The developed method was validated as per the ICH analytical method validation guidelines. All validation parameters were within the acceptable range. The assay methods were found to be linear from 80-240 µg/ml for Sofosbuvir and 20-60µg/ml for Velpatasvir. The correlation coefficient was 0.9998 and 0.9992 for velpatasvir and sofosbuvir respectively.  The mean percentage recovery for the developed method was found to be in the range of 98.4-100.4% for velpatasvir and 98.6-100.6% for sofosbuvir. The developed method was also found to be robust
Conclusion: The developed method was found to be suitable for the routine quantitative analysis of Velpatasvir and Sofosbuvir in bulk and pharmaceutical dosage form. It was also concluded that developed method was accurate, precise, linear, reproducible, robust, and sensitive.Â
Downloads
References
ICH. Q2A Validation of Analytical Procedure: Methodology International Conference on Harmonization. Geneva: ICH; 1994.
Chakravarthy A, Bbv S, Kumar P. Method development and validation of ultraviolet-visible spectroscopic method for the estimation of hepatitis-c drugs-daclatasvir and sofosbuvir in active pharmaceutical ingredient form. Asian J Pharm Clin Res 2016;9:61-6.
Zaman B, Siddique F, Hassan W. RP-HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies. Chromatographia 2016;79:1605-13.
Hassouna EM, Abdelrahman MM, Mohamed MA. Assay and dissolution methods development and validation for simultaneous determination of sofosbuvir and ledipasvir by RP-HPLC method in tablet dosage forms. J Forensic Sci Crim Invest 2017;1:505-9.
Devilal J, Durgaprasa B, Narottam P, Srinivasa A. New method development and validation for the determination of ledipasvir in bulk drug form by using reverse phase HPLC technique. World J Pharm Pharm Sci 2016;5:1312-21.
Nagaraju T, Vardhan SV, Kumar DR, Ramachandran D. A new RP-HPLC method for the simultaneous assay of SOFOSBUVIR and ledipasvir in combined dosage form. Int J Chemtech Res 2017;10:761-8.
Rezk MR, Basalious EB, Karim IA. Development of a sensitive UPLC-ESIMS/MS method for quantification of SOFOSBUVIR and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study. J Pharm Biomed Anal 2015;114:97-104.
Madhavi S, Prameelarani A. Bioanalytical method development and validation for the determination of SOFOSBUVIR from human plasma. Int J Pharm Pharm Sci 2017;9:35-41.
Ravichandran V, Shalini S, Sundaram KM, Rajak H. Validation of analytical methods-strategies and importance. Int J Pharm Pharm Sci 2010;2:18-22.
Vejendla R, Subramanyam CV, Veerabhadram G. Estimation, and validation of SOFOSBUVIR in bulk and tablet dosage form by RP-HPLC. Int J Pharm 2016;6:121-7.
Pan C, Chen Y, Chen W, Zhou G, Jin L, Zheng Y, et al. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1008:255-9.
ICH. Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology in Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005.
United States Food and Drug Administration. Guidance for Industry: Analytical Procedures and Methods Validation: Chemistry, Manufacturing, and Controls Documentation. Rockville, MD: Draft Guidance USFDA; 2001.
Shi X, Zhu D, Lou J, Zhu B, Hu AR, Gan D. Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2015;1002:353-7.
Bunchorntavakul C, Reddy KR. Review article: The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015;42:258-72.
Sundaram V, Kowdley KV. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2016;10:13-20.
Patel MM, Patel HD. Development and validation of RP-HPLC method for simultaneous estimation of terbinafine hydrochloride and mometasone furoate in combined dosage form. Int J Pharm Pharm Sci 2014;6:106-9.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
